Editorial commentary: Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses

Clinical Infectious Diseases

Volumn 41, Issue 2, 2005, Pages 252-254

  Katzenstein, David ^a   Ogden, Richard ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

CRF02 AG VIRUS; DRUG EFFICACY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NOTE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; VIRUS RESISTANCE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MULTIDRUG RESISTANCE;

DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS;

EID: 21844444105     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431212     Document Type: Note

References (12)

1. Kinomoto M, Appiah-Opong R, Brandful JAM, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis 2005; 41:243-51 (in this issue).
2. Park L, Goulder P, Kiepiela P, et al. HLA-restricted immune responses have driven the evolution of HIV-1 clades [abstract 451]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
3. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48:2159-65.
4. Turner D, Brenner B, Moisi D, et al. Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:2993-8.
5. Gonzalez LM, Brindeiro RM, Aguiar RS, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004; 48:3552-5.
6. Deshpande A, Recordon-Pinson P, Deshmukh R, et al. Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004; 20:1032-5.
7. Tee KK, Pon CK, Kamarulzaman A, Ng KP. Emergence of HIV-1 CRF01_AE/B unique recombinant forms in Kuala Lumpur, Malaysia. AIDS 2005; 19:119-26.
8. Cerqueira DM, Amorim RM, Silva RR, Camara GN, Brigido MM, Martins CR. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 2004; 99:877-82.
9. Nukoolkarn S, Pongthapisith V, Panyim S, Leelamanit W. Sequence variability of the HIV type 1 protease gene in Thai patients experienced with antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:1368-72.
10. Kantor R, Katzenstein D, Efron B, et al. The impact of HIV-1 diversity and antiretroviral therapy on RT and protease genotypic evolution. PLoS Med 2005; 2:e112.
11. Wlodawer A, Vondrasek J. Inhibitors of HIV protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27:249-84.
12. Collins JR, Burk SK, Erickson J. Flap opening in HIV-1 protease simulated by "activated" molecular dynamics. Nat Struct Biol 1995; 2: 334-8.